M2 PRESSWIRE-September 3, 2019-: Oral Cancer Therapeutics
Market - Global Forecast and Analysis 2019-2023: Development of Nanotechnology-Based Drug Delivery Systems
ENPNewswire-August 28, 2019--Kintai Therapeutics Announces Collaborations with Leading Academic Centers to Identify Novel Targets for Cancer Therapeutics
Siamab Therapeutics, a biopharmaceutical company developing novel glycan-targeted cancer therapeutics
, has signed a contract with an undisclosed, large commercial-stage biopharmaceutical company, it was reported yesterday.
Summary: The global peptide based cancer therapeutics
market will surpass a valuation of US$ 11,160 Mn by 2022-end, expanding at an impressive CAGR of 9.2%.
MBF Therapeutics currently plans to incorporate SwRI's technology to develop vaccines for canine cancer therapeutics
Shares of Tyme Technologies a clinical-stage biotechnology company that develops novel cancer therapeutics
, spiked almost 50% in regular session trading on Tuesday after announcing earlier, that its management team will hold a conference call with analysts and investors at 9 AM EST on Friday, January 18, to discuss the SM-88 preliminary Phase II pancreatic cancer data scheduled to be presented in four posters at the American Society of Clinical Oncology's Gastrointestinal Cancers Symposium or ASCO GI, being held later this week.
[USPRwire, Thu Jan 10 2019] Peptide based cancer therapeutics
are yet to become widespread, but the initial low numbers certainly do not suggest any pessimism in the global market.
Specific topics include pharmacogenomics and the role of genomics in cancer therapeutics
, alkylating and methylating agents, targeted therapy in non-small cell lung cancer, the endocrine therapy of breast cancer, and hematopoietic growth factors.
They hope to confirm the results, in Molecular Cancer Therapeutics
journal, in clinical trials.
The global non-small cell lung cancer therapeutics
market report estimates the market size (Revenue USD million - 2014 to 2021) for key market segments based on the drug classes (angiogenesis inhibitors - Avastin, Cyramza; epidermal growth factor receptor blockers - Tarceva, Gilotrif, Iressa; Folate antimetabolites - Alimta; kinase inhibitors - Xalkori, Zykadia; microtubule stabilizers - Abraxane, Docetaxel; and PD-1/ PD-L1 inhibitors - Opdivo, Keytruda), clinical pipeline analysis of phase 1, 2 and 3 drugs (Avelumab, MPDL3280A, MEDI4736, Abemaciclib, etc.), and forecasts growth trends (CAGR% - 2017 to 2021).
Australian drug development company Bionomics Limited (ASX:BNO, OTCQX:BNOEF) has received US$736,815 in licensing funds as part of an agreement between MSD (known as Merck in the US & Canada) and Cancer Research Technologies (CRT) on behalf of the Australian Cooperative Research Centre for Cancer Therapeutics